An interesting round up of the Top 10 Sequencing Companies from Genetic Engineering & Biotechnology News highlights the dominance of Illumina on the life-sciences (genomics) industry.
With giants like Grail and Human Longevity, as well as a very healthy research community and a rapidly growing diagnostics community, Illumina look to have a good future ahead of them!
The Top 10 “sequencing” companies:
#1. Illumina $2.752 billion in 2017
#2. Thermo Fisher Scientific “Just under” $418.36 million in 2017
#3. BGI Genomics $332.3 million
#4. Agilent Technologies approximately $230 million
#5. Qiagen More than $115 million
#6. Macrogen $95.4 million
#7. PacBio $93.5 million
#8. Genewiz $83.1 million
#9. 10x Genomics $71 million
#10. Oxford Nanopore Technologies $6.3 million
Considering all the companies in the top 10 except ONT and PacBio are “feeding” ILMN sequencers, the massive revenue for ILMN is to be expected, as is the gap. The number 2 spot will become interesting in 2018 as AmpliSeq kits move to ILMN sequencers and BGI start selling machines and reagents globally.
And don’t forget Grail and Helix both are businesses that are likely to become major revenue streams for Illumina. Grail are going to go deep on genomes and ctDNA burning lots of Illumina reagents.
Helix is perhaps more interesting as Illumina sell reagents to Helix but also get back recurring and highly scalable revenue on the Helix App store. Whether this would ever get to be as big a proportion of Illumina’s revenue as Apples remains to be seen!